SCHEMBL855685

SCHEMBL855685

COc1ccc2c(Cl)nc(CN(C)C)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
GFER P55789 1/20 0.47
KDM4E B2RXH2 6/20 0.46
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.40
HBB P68871 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTR2A P28223 2/20 0.40
SLC6A4 P31645 2/20 0.40
ACHE P22303 1/20 0.40
KCNH2 Q12809 1/20 0.40
APP P05067 1/20 0.39
LMNA P02545 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TACR3 P29371 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9288756 0.84 NPSR1 (0.51) ALDH1A1KDM4ECYP2D6TSHRHBB
SCHEMBL858910 0.84 ALDH1A1 (0.50) ALDH1A1GFERKDM4ETSHRHBB
SCHEMBL29589773 0.84 ALDH1A1 (0.50) ALDH1A1GFERKDM4ETSHRHBB
SCHEMBL855744 0.83 CYP2D6 (0.41) ALDH1A1KDM4ECYP2D6HTR2AAPP
SCHEMBL15429597 0.81 HTR2A (0.39) ALDH1A1KDM4ECYP2D6TSHRHBB
SCHEMBL6119690 0.79 ENPP1 (0.44) KDM4ELMNAGLAGAAKDM1A
SCHEMBL13729976 0.78 APP (0.45) ALDH1A1GFERKDM4EL3MBTL1ACHE
SCHEMBL2173715 0.77 ALDH1A1 (0.47) ALDH1A1GFERKDM4EL3MBTL1ACHE
SCHEMBL30014091 0.77 ALDH1A1 (0.47) ALDH1A1GFERKDM4EL3MBTL1ACHE
SCHEMBL857219 0.75 KDM4E (0.49) ALDH1A1GFERKDM4ETSHRHBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3395/4885GFER 3964/4885KDM4E 610/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3533/4885GFER 4111/4885KDM4E 361/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3049/4885GFER 4167/4885KDM4E 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.